A single protein may be holding back CAR T cancer therapy
A newly identified protein may be one of the biggest obstacles holding CAR T-cell therapy back. Researchers found that NFIL3 causes these engineered immune cells to become exhausted and lose their cancer-fighting power over time. When NFIL3 was disabled, the cells remained stronger for longer and controlled tumors more effectively in animal models.
Original Source
Read the full article at Sciencedaily →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.